Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Benitec Biopharma Inc is a biotechnology business based in the US. Benitec Biopharma shares (BNTC) are listed on the NASDAQ and all prices are listed in US Dollars. Benitec Biopharma employs 14 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.71|
|52-week range||$2.30 - $9.19|
|50-day moving average||$4.11|
|200-day moving average||$4.28|
|Wall St. target price||$14.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||16.30%|
|3 months (2021-05-04)||14.04%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
|Gross profit TTM||$287,000|
|Return on assets TTM||-58.45%|
|Return on equity TTM||-110.15%|
|Market capitalisation||$30 million|
TTM: trailing 12 months
There are currently 199,515 Benitec Biopharma shares held short by investors – that's known as Benitec Biopharma's "short interest". This figure is 14.2% down from 232,444 last month.
There are a few different ways that this level of interest in shorting Benitec Biopharma shares can be evaluated.
Benitec Biopharma's "short interest ratio" (SIR) is the quantity of Benitec Biopharma shares currently shorted divided by the average quantity of Benitec Biopharma shares traded daily (recently around 107266.12903226). Benitec Biopharma's SIR currently stands at 1.86. In other words for every 100,000 Benitec Biopharma shares traded daily on the market, roughly 1860 shares are currently held short.
However Benitec Biopharma's short interest can also be evaluated against the total number of Benitec Biopharma shares, or, against the total number of tradable Benitec Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Benitec Biopharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Benitec Biopharma shares in existence, roughly 20 shares are currently held short) or 0.0333% of the tradable shares (for every 100,000 tradable Benitec Biopharma shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Benitec Biopharma.
Find out more about how you can short Benitec Biopharma stock.
We're not expecting Benitec Biopharma to pay a dividend over the next 12 months.
Benitec Biopharma's shares were split on a 2:3 basis on 14 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Benitec Biopharma shares – just the quantity. However, indirectly, the new 50% higher share price could have impacted the market appetite for Benitec Biopharma shares which in turn could have impacted Benitec Biopharma's share price.
Over the last 12 months, Benitec Biopharma's shares have ranged in value from as little as $2.3 up to $9.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Benitec Biopharma's is 1.6888. This would suggest that Benitec Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Benitec Biopharma Inc. , a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.